Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

Confirmed adenocarcinomas of the prostate.
Evidence of metastatic disease
Evidence of disease progression including one of the following: increasing levels of PSA, progressive lymph node disease, or worsening bone scan
PSA level is greater or equal to 7 ng/ml.
ECOG performance status less than or equal to 1

Previously received bicalutamide, flutamide, or nilutamide within the past 12 months (except for a period of use less than 30 days long).
Prior chemotherapy for prostate cancer
Prior rapamycin or rapamycin analogs, including ridaforolimus, everolimus, or temsirolimus.
Patient is receiving an opioid or narcotic analgesic for pain due to prostate cancer
Patient has pain related to prostate cancer that warrants the initiation of chemotherapy

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)